Generation of donor-derived Wilms tumor antigen 1–specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study

Cytotherapy ◽  
2019 ◽  
Vol 21 (9) ◽  
pp. 958-972
Author(s):  
Federica Ferulli ◽  
Matteo Tanzi ◽  
Ilaria Turin ◽  
Enrica Montini ◽  
Vittorio Rosti ◽  
...  
Keyword(s):  
Stem Cell ◽  
Clinical Study ◽  
T Lymphocytes ◽  
Cell Therapy ◽  
Stem Cell Transplantation ◽  
Somatic Cell ◽  
Cytotoxic T Lymphocytes ◽  
Tumor Antigen ◽  
Wilms Tumor ◽  
Somatic Cell Therapy

scholarly journals Identification of Two New HLA-A*1101-Restricted Tax Epitopes Recognized by Cytotoxic T Lymphocytes in an Adult T-Cell Leukemia Patient after Hematopoietic Stem Cell Transplantation

2005 ◽  
Vol 79 (15) ◽  
pp. 10088-10092 ◽  
Author(s):  
Nanae Harashima ◽  
Ryuji Tanosaki ◽  
Yukiko Shimizu ◽  
Kiyoshi Kurihara ◽  
Takao Masuda ◽  
...  
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
T Lymphocytes ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cytotoxic T Lymphocytes ◽  
Cell Leukemia ◽  
Hematopoietic Stem ◽  
Adult T Cell Leukemia

ABSTRACT We previously reported that Tax-specific CD8+ cytotoxic T lymphocytes (CTLs), directed to single epitopes restricted by HLA-A2 or A24, expanded in vitro and in vivo in peripheral blood mononuclear cells (PBMC) from some adult T-cell leukemia (ATL) patients after but not before allogeneic hematopoietic stem cell transplantation (HSCT). Here, we demonstrated similar Tax-specific CTL expansion in PBMC from another post-HSCT ATL patient without HLA-A2 or A24, whose CTLs equally recognized two newly identified epitopes, Tax88-96 and Tax272-280, restricted by HLA-A11, suggesting that these immunodominant Tax epitopes are present in the ATL patient in vivo.

T-cell therapy for viral infections

Hematology ◽  
2013 ◽  
Vol 2013 (1) ◽  
pp. 342-347 ◽  
Author(s):  
Helen E. Heslop ◽  
Ann M. Leen
Keyword(s):  
Stem Cell ◽  
T Cell ◽  
Cell Therapy ◽  
Stem Cell Transplantation ◽  
Cytotoxic T Lymphocytes ◽  
Viral Infections ◽  
Hemopoietic Stem Cell ◽  
Viral Diseases ◽  
T Cell Therapy ◽  
Hemopoietic Stem Cell Transplantation

Abstract Viral infections remain a major cause of morbidity in patients with immunodeficiency, such as recipients of hemopoietic stem cell transplantation. Adoptive transfer of donor-derived virus-specific cytotoxic T lymphocytes is a strategy to restore virus-specific immunity to prevent or treat viral diseases and has been tested in the clinical setting for more than 20 years. Several different groups have used expanded virus-specific T-cell products specific for one or multiple viruses to both reconstitute antiviral immunity after transplantation and to treat active viral infections. Response rates are encouraging, although resistance has been seen when the infused cell population has had restricted specificity or has targeted antigens expressed in donor-infected but not virally infected recipient cells. The goal of current trials is to make this approach more broadly applicable using more rapidly available products from the donor, such as directly selected or briefly expanded cells or closely matched banked cells.

Sign in / Sign up

Export Citation Format

Share Document